NPI 1487880050: Open Payments
NPI 1487880050. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,369 in 61 payments from 14 companies in 2025. Trend: 2023 $1,853 · 2024 $1,840 · 2025 $1,369
Food & beverage: $1,369
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $420 |
| Otsuka America Pharmaceutical, Inc. | 13 | $224 |
| Alkermes, Inc. | 6 | $122 |
| Vanda Pharmaceuticals Inc. | 4 | $84 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| ABBVIE INC. | 3 | $73 |
| E.R. Squibb & Sons, L.L.C. | 3 | $57 |
| Lundbeck LLC | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
Products named: CAPLYTA, REXULTI, ARISTADA, FANAPT, Auvelity, TRINTELLIX, VRAYLAR, COBENFY.
